Mazzarello Andrea Nicola, Koroveshi Brisejda, Guardo Daniela, Lanza Lorella, Ghiotto Fabio, Bruno Silvia, Cappelli Enrico
Department of Experimental Medicine, University of Genoa, Via De Toni 14, 16132 Genova, Italy.
Laboratory of Clinical Pathology, ASL2 Liguria, S. Paolo Hospital, 17100 Savona, Italy.
J Clin Med. 2023 Jan 28;12(3):998. doi: 10.3390/jcm12030998.
Recently, cases of fortuitous discovery of Chronic Lymphocytic Leukemia (CLL) during hospitalization for Coronavirus disease (COVID-19) have been reported. These patients did not show a monoclonal B cell expansion before COVID-19 but were diagnosed with CLL upon a sudden lymphocytosis that occurred during hospitalization. The (hyper)lymphocytosis during COVID-19 was also described in patients with overt CLL disease. Contextually, lymphocytosis is an unexpected phenomenon since it is an uncommon feature in the COVID-19 patient population, who rather tend to experience lymphopenia. Thus, lymphocytosis that arises during COVID-19 infection is a thought-provoking behavior, strikingly in contrast with that observed in non-CLL individuals. Herein, we speculate about the possible mechanisms involved with the observed phenomenon. Many of the plausible explanations might have an adverse impact on these CLL patients and further clinical and laboratory investigations might be desirable.
最近，有报告称在因冠状病毒病（COVID-19）住院期间偶然发现慢性淋巴细胞白血病（CLL）的病例。这些患者在感染COVID-19之前未出现单克隆B细胞扩增，但在住院期间突然发生淋巴细胞增多症后被诊断为CLL。明显患有CLL疾病的患者在感染COVID-19期间也出现了（高）淋巴细胞增多症。在此背景下，淋巴细胞增多是一种意外现象，因为它在COVID-19患者群体中并不常见，这些患者更倾向于出现淋巴细胞减少。因此，COVID-19感染期间出现的淋巴细胞增多是一种发人深省的现象，与非CLL个体中观察到的情况形成鲜明对比。在此，我们推测了与观察到的现象相关的可能机制。许多看似合理的解释可能会对这些CLL患者产生不利影响，可能需要进一步进行临床和实验室研究。
